2026-07-21T08:48:45Zhttps://repisalud.isciii.es/rest/oai/request
oai:repisalud.isciii.es:20.500.12105/231152024-11-28T16:19:59Zcom_20.500.12105_2173com_20.500.12105_2051com_20.500.12105_15322col_20.500.12105_19597col_20.500.12105_16938
Repisalud author Rodríguez-García, Alba author Mennesson, Nicolas author Hernandez-Ibarburu, Gema author Morales, María Luz author Garderet, Laurent author Bouchereau, Lorine author Allain-Maillet, Sophie author Piver, Eric author Marbán, Irene author Rubio, David author Bigot-Corbel, Edith author Martinez-Lopez, Joaquin author Linares, María author Hermouet, Sylvie funder Ligue Nationale Contre le Cancer (Francia) funder Spanish Society of Hematology 2024-09-16T08:17:10Z 2024-09-16T08:17:10Z 2024-01-01 Haematologica . 2024 ;109(1):272-282. 10.3324/haematol.2023.283096 1592-8721 Haematologica 37199121 https://hdl.handle.net/20.500.12105/23115 Subsets of multiple myeloma (MM) and monoclonal gammopathies of undetermined significance (MGUS) present with a monoclonal immunoglobulin specific for hepatitis C virus (HCV), thus are presumably HCV-driven, and antiviral treatment can lead to the disappearance of antigen stimulation and improved control of clonal plasma cells. Here we studied the role of hepatitis B virus (HBV) in the pathogenesis of MGUS and MM in 45 HBV-infected patients with monoclonal gammopathy. We analyzed the specificity of recognition of the monoclonal immunoglobulin of these patients and validated the efficacy of antiviral treatment (AVT). For 18 of 45 (40%) HBV-infected patients, the target of the monoclonal immunoglobulin was identified: the most frequent target was HBV (n=11), followed by other infectious pathogens (n=6) and glucosylsphingosine (n=1). Two patients whose monoclonal immunoglobulin targeted HBV (HBx and HBcAg), implying that their gammopathy was HBV-driven, received AVT and the gammopathy did not progress. AVT efficacy was then investigated in a large cohort of HBV-infected MM patients (n=1367) who received or did not receive anti-HBV treatments and compared to a cohort of HCV-infected MM patients (n=1220). AVT significantly improved patient probability of overall survival (P=0.016 for the HBV-positive cohort, P=0.005 for the HCV-positive cohort). Altogether, MGUS and MM disease can be HBV- or HCV-driven in infected patients, and the study demonstrates the importance of AVT in such patients. eng Impact of viral hepatitis therapy in multiple myeloma and other monoclonal gammopathies linked to hepatitis B or C viruses research article